LOADING
Loading...

Our Expertise

During a 20 year span, we have completed over 340 clinical trials of various phases in over 25 therapeutic areas for 92 clients from more than 20 countries.

All
Q1
Q2
Q3
Q4

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Our Expertise by Phase and Therapeutic Area

During 20 years of operation, we have completed 178 phase III clinical trials, 25 phase II clinical trials, 16 phase I clinical trials, 39 bioequivalence studies, and 77 observational clinical trials.

The most demanded therapeutic areas for Synergy are oncology, respiratory diseases, cardiology, neurology and gastroenterology. Russia and Kazakhstan are the most demanded regions for conducting clinical trials. Studies involving healthy volunteers make up 15% of our experience.

All
Q1
Q2
Q3
Q4

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Our Expertise by Product Type

Approximately 60% of our clinical trials are related to the study of low molecular weight chemical compounds; the subject of research for the remaining 40% of projects are high molecular biological substances.

The most demanded therapeutic areas in this category of clinical trials (except for the studies of the pharmacological effects on healthy volunteers) for Synergy are oncology, respiratory diseases, neurology, cardiology, endocrine and infectious diseases.

All
Q1
Q2
Q3
Q4

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Our Expertise with Biosimilar Drugs

We love and know how to work with Sponsors manufacturing biosimilars. Synergy have successfully implemented 18 projects with biosimilars in 6 therapeutic areas, including testing the pharmacological effects of medicines on healthy volunteers, as well as in patients with diseases of the endocrine, circulatory and respiratory systems.